Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corporation - Common Stock (NQ: GERN )

1.760 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,023
Open 1.760
Bid (Size) 1.760 (3)
Ask (Size) 1.780 (33)
Prev. Close 1.760
Today's Range 1.760 - 1.760
52wk Range 1.460 - 5.340
Shares Outstanding 508,766,846
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Geron Stock Is Plummeting Today
Via The Motley Fool
What's going on in today's session
Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill

Performance

YTD
-51.11%
-51.11%
1 Month
-38.68%
-38.68%
3 Month
-56.44%
-56.44%
6 Month
-60.00%
-60.00%
1 Year
-15.38%
-15.38%

More News

Read More
Dow Dips Over 100 Points; TJX Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Here are the top movers in Wednesday's session.
Via Chartmill
Earnings Scheduled For February 26, 2025
Via Benzinga
4 Analysts Assess Geron: What You Need To Know
Via Benzinga
Analyst Scoreboard: 4 Ratings For Geron
Via Benzinga
Nasdaq Surges 150 Points; Lowe's Posts Upbeat Earnings
Via Benzinga
Geron (GERN) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Traders are paying attention to the gapping stocks in Wednesday's session.
Via Chartmill
Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Geron Corporation
Via Business Wire
Geron to Participate at Upcoming Investor Conferences in March 2025
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
From Geron Corporation
Via Business Wire
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
From Geron Corporation
Via Business Wire
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
From Geron Corporation
Via Business Wire
Geron to Participate in the Stifel 2024 Healthcare Conference
From Geron Corporation
Via Business Wire
Geron (GERN) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.